Windtree Therapeutics (NASDAQ: WINT), a biotechnology firm, faces an imminent delisting from the Nasdaq exchange, effective August 21, 2025. This significant action stems from the company’s prolonged failure to meet the exchange’s critical minimum bid price requirement, signaling severe financial distress and a substantial blow to its public market presence.
- Windtree Therapeutics (NASDAQ: WINT) is set for delisting from Nasdaq on August 21, 2025.
- The primary reason is non-compliance with Nasdaq Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share.
- Trading in Windtree’s common stock will be suspended on the specified delisting date.
- The company’s shares have plunged over 90% in the last month and more than 99% since the beginning of the year.
- CEO Jed Latkin acknowledged the formal notification of non-compliance in an SEC filing.
- Nasdaq previously delisted Bitcoin mining firm Argo Blockchain (ARGO) for the identical rule violation.
Nasdaq Delisting Details
Non-Compliance with Minimum Bid Price Rule
According to a recent filing with the U.S. Securities and Exchange Commission (SEC), Windtree Therapeutics officially confirmed its non-compliance with Nasdaq Rule 5550(a)(2). This crucial rule mandates that all listed securities must maintain a minimum bid price of $1.00 per share to ensure market stability and investor confidence. The formal notification from Nasdaq confirms that trading in Windtree’s common stock will be suspended on the designated date, as explicitly acknowledged by CEO Jed Latkin in the regulatory document.
Catastrophic Stock Performance
The company’s shares have endured a severe downturn, experiencing a catastrophic decline of over 90% in the past month alone and more than 99% since the beginning of the year, based on data provided by Yahoo Finance. On a recent Wednesday, the stock further plummeted by 76% to $0.11 before market close. Windtree’s stock initially fell below the $1 threshold in May and has since been unable to sustain any meaningful recovery, directly leading to the current delisting predicament.
Broader Context and Regulatory Precedent
This enforcement action by Nasdaq is consistent with its stringent application of listing standards. The exchange rigorously applies these rules to uphold market integrity and protect investor confidence. A notable parallel occurred recently in July, when Nasdaq similarly delisted Bitcoin mining firm Argo Blockchain (ARGO) for the identical violation of the minimum bid price rule. This serves to underscore Nasdaq’s unwavering adherence to its regulatory framework for all listed entities, irrespective of their industry sector.
Sophia Patel brings deep expertise in portfolio management and risk assessment. With a Master’s in Finance, she writes practical guides and in-depth analyses to help investors build and protect their wealth.